Amphastar Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMPH)

$19.20 +0.36 (+1.91 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$18.84
Today's Range$18.78 - $19.23
52-Week Range$12.05 - $19.95
Volume184,651 shs
Average Volume169,580 shs
Market Capitalization$861.13 million
P/E Ratio124.87
Dividend YieldN/A
Beta1.51

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484

Debt

Debt-to-Equity Ratio0.13%
Current Ratio3.08%
Quick Ratio1.86%

Price-To-Earnings

Trailing P/E Ratio124.87
Forward P/E Ratio-480.00
P/E Growth1.31

Sales & Book Value

Annual Sales$255.16 million
Price / Sales3.46
Cash Flow$0.56 per share
Price / Cash34.35
Book Value$7.15 per share
Price / Book2.69

Profitability

Trailing EPSN/A
Net Income$10.53 million
Net Margins0.12%
Return on Equity2.30%
Return on Assets1.74%

Miscellaneous

Employees1,541
Outstanding Shares45,980,000

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How will Amphastar Pharmaceuticals' stock buyback program work?

Amphastar Pharmaceuticals announced that its board has approved a stock repurchase plan on Thursday, August 10th 2017, which authorizes the company to repurchase $20,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its stock is undervalued.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) posted its quarterly earnings results on Wednesday, November, 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.02 by $0.05. The business had revenue of $57.90 million for the quarter, compared to analyst estimates of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The business's revenue for the quarter was down 9.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 EPS. View Amphastar Pharmaceuticals' Earnings History.

Where is Amphastar Pharmaceuticals' stock going? Where will Amphastar Pharmaceuticals' stock price be in 2018?

6 brokerages have issued 12-month target prices for Amphastar Pharmaceuticals' shares. Their forecasts range from $17.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $20.60 in the next twelve months. View Analyst Ratings for Amphastar Pharmaceuticals.

What are Wall Street analysts saying about Amphastar Pharmaceuticals stock?

Here are some recent quotes from research analysts about Amphastar Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. " (1/23/2018)
  • 2. Piper Jaffray Companies analysts commented, "Amphastar reported 4Q16 diluted EPS of $0.01 on revenues of $63.5M, compared to Street estimates of ($0.01) and $55.9M, respectively. Though the base business is facing some challenges as we move further into 2017 (i.e., uncertainty over the trajectory of generic enoxaparin; the potential removal of AMPH's injectable epinephrine given that it is an unapproved product), we nonetheless remain bullish on AMPH shares, given that the pipeline continues to advance and given our view that it very much has the potential to drive transformative longer-term cash generation (AMPH also being one of the few generics companies solely focused on more complex dosage forms also doesn't hurt). We reiterate our Overweight rating and are lowering our PT to $20 from $22 (see below for more details)." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, " AMPH reported 4Q16 revenue of $63.5mm vs. BMO/consensus $56.5mm/ $55.9mm and adj. EPS of $0.01 vs. BMO/consensus $0.02/($0.01). Revenue upside was offset by lower gross margin and higher R&D. Without 2017 revenue/EPS guidance, there is some uncertainty with the numbers given a number of moving parts, including Enoxaparin sales, potential withdrawal of Epinephrine vials, overall pricing pressure, contribution from new approvals, and higher spending levels to invest in the pipeline. We are lowering estimates and our target goes to $16 from $18. The pipeline has value, but we await near-term execution." (3/14/2017)
  • 4. Needham & Company LLC analysts commented, "While AMPH reported 4Q16 results that bested the Street's expectations on both top and bottom lines, the company has taken its lumps from the FDA over the last three months. Two recent CRLs (Primatene Mist and intranasal naloxone) have delayed two branded product opportunities by at least 12 months. FDA recently requested that AMPH discontinue the distribution of its epinephrine vial product, which generated $18.6MM in 2016 revenues. The last shot on goal in terms of potential near-term approvals is an ANDA product (undisclosed injectable), which AMPH mgmt expects will make meaningful sales contributions in 2017. The ANDA product pipeline is expected to make additional contributions in 2018. We maintain our Buy rating and adjust our PT to $18 (from $20) to account for a reduction in base business revenues." (3/14/2017)

Who are some of Amphastar Pharmaceuticals' key competitors?

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the folowing people:

  • Mary Ziping Luo Ph.D., Chief Operating Officer, Chief Scientist and Chairman of the Board (Age 67)
  • Jason B. Shandell J.D., President, General Counsel, Director (Age 43)
  • Jack Yongfeng Zhang Ph.D., Chief Executive Officer, Chief Scientific Officer, Director (Age 70)
  • William J. Peters, Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc. (Age 49)
  • Diane G. Gerst, Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc (Age 57)
  • Rong Zhou, Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc. (Age 58)
  • Michael A. Zasloff M.D. Ph.D., Lead Independent Director (Age 71)
  • Richard Koo CPA, Independent Director (Age 76)
  • Howard S. Lee Ph.D., Independent Director (Age 54)
  • Floyd F. Petersen, Independent Director (Age 73)

Who owns Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.88%), UBS Asset Management Americas Inc. (0.87%), Geode Capital Management LLC (0.72%), Millennium Management LLC (0.64%), Cornerstone Capital Management Holdings LLC. (0.56%) and Fisher Asset Management LLC (0.50%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Who sold Amphastar Pharmaceuticals stock? Who is selling Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Bank of New York Mellon Corp, Cornerstone Capital Management Holdings LLC., Acadian Asset Management LLC, Metropolitan Life Insurance Co. NY, TIAA CREF Investment Management LLC, Teachers Retirement System of The State of Kentucky and State of Tennessee Treasury Department. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Who bought Amphastar Pharmaceuticals stock? Who is buying Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Wells Fargo & Company MN, Alliancebernstein L.P., Arizona State Retirement System, MetLife Investment Advisors LLC, Fisher Asset Management LLC, Teacher Retirement System of Texas and Driehaus Capital Management LLC. View Insider Buying and Selling for Amphastar Pharmaceuticals.

How do I buy Amphastar Pharmaceuticals stock?

Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $19.20.

How big of a company is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals has a market capitalization of $861.13 million and generates $255.16 million in revenue each year. Amphastar Pharmaceuticals employs 1,541 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]


MarketBeat Community Rating for Amphastar Pharmaceuticals (AMPH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  322
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.60$19.20$20.33$19.83
Price Target Upside: 8.88% upside1.99% downside6.46% upside33.20% upside

Amphastar Pharmaceuticals (NASDAQ:AMPH) Consensus Price Target History

Price Target History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/30/2018Piper Jaffray CompaniesReiterated RatingBuy$26.00MediumView Rating Details
12/1/2017Needham & Company LLCBoost Price TargetBuy$20.00 -> $23.00MediumView Rating Details
11/10/2017BMO Capital MarketsBoost Price TargetMarket Perform$16.00 -> $17.00N/AView Rating Details
11/9/2017Raymond James FinancialDowngradeOutperform -> Market Perform$18.00N/AView Rating Details
10/29/2017Jefferies GroupSet Price TargetBuy$19.00N/AView Rating Details
7/22/2017Wells Fargo & CoReiterated RatingBuyMediumView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings History and Estimates Chart

Earnings by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ AMPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017$0.02$0.07$57.23 million$57.90 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.06$0.11$63.40 million$65.20 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.06$0.03$63.74 million$56.67 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.01)$0.01$55.78 million$63.54 millionViewN/AView Earnings Details
11/8/2016Q3$0.03$0.14$65.12 million$64.20 millionViewListenView Earnings Details
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.20)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.11)($0.11)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.11)$0.02$44.23 million$49.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.04 EPS
Next Year EPS Consensus Estimate: $0.57 EPS

Dividends

Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 44.28%
Insider Trades by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/26/2018Jason B. ShandellInsiderSell18,627$19.42$361,736.34View SEC Filing  
1/25/2018Jason B. ShandellGeneral CounselSell8,661$19.26$166,810.86View SEC Filing  
12/19/2017Diane G GerstEVPSell523$19.48$10,188.0430,164View SEC Filing  
12/14/2017Stephen B ShohetDirectorSell7,866$18.87$148,431.4231,982View SEC Filing  
12/12/2017Diane G GerstEVPSell523$18.96$9,916.0830,687View SEC Filing  
12/7/2017Stephen B ShohetDirectorSell7,862$18.34$144,189.0831,978View SEC Filing  
12/1/2017William J. PetersCFOSell6,226$19.67$122,465.42View SEC Filing  
11/30/2017Stephen B ShohetDirectorSell7,862$19.25$151,343.5031,978View SEC Filing  
11/28/2017Diane G GerstEVPSell523$18.15$9,492.4531,210View SEC Filing  
11/22/2017Stephen B ShohetDirectorSell7,862$18.94$148,906.2831,978View SEC Filing  
11/21/2017Diane G GerstEVPSell523$18.81$9,837.6331,733View SEC Filing  
11/16/2017Stephen B ShohetDirectorSell7,862$18.04$141,830.4831,978View SEC Filing  
11/15/2017Diane G GerstEVPSell523$17.77$9,293.7132,256View SEC Filing  
11/9/2017Stephen B ShohetDirectorSell7,862$18.55$145,840.1031,978View SEC Filing  
11/7/2017Diane G GerstEVPSell523$17.93$9,377.3932,779View SEC Filing  
11/2/2017Stephen B ShohetDirectorSell7,862$18.37$144,424.94View SEC Filing  
10/26/2017Stephen B ShohetDirectorSell7,862$18.39$144,582.1831,978View SEC Filing  
10/24/2017Diane G GerstEVPSell523$18.29$9,565.6733,302View SEC Filing  
10/19/2017Stephen B ShohetDirectorSell7,862$18.34$144,189.0831,978View SEC Filing  
10/17/2017Diane G GerstEVPSell523$18.48$9,665.0433,825View SEC Filing  
10/13/2017William J PetersCFOSell3,026$18.56$56,162.56View SEC Filing  
10/12/2017Stephen B ShohetDirectorSell7,862$18.73$147,255.26View SEC Filing  
10/5/2017Diane G GerstEVPSell8,444$18.87$159,338.28View SEC Filing  
10/4/2017Floyd F PetersenDirectorSell39,312$18.59$730,810.08View SEC Filing  
10/2/2017Michael A ZasloffDirectorSell63,624$18.18$1,156,684.32101,879View SEC Filing  
8/15/2017Richard K PrinsDirectorSell10,000$14.81$148,100.0033,844View SEC Filing  
8/14/2017Richard K PrinsDirectorSell5,000$14.80$74,000.0033,844View SEC Filing  
6/9/2017Richard K PrinsDirectorSell10,000$17.07$170,700.0028,844View SEC Filing  
6/1/2017Michael A ZasloffDirectorSell15,000$17.01$255,150.0047,411View SEC Filing  
5/31/2017Jason B ShandellDirectorSell11,482$16.92$194,275.44241,342View SEC Filing  
5/11/2017Richard K PrinsDirectorSell7,500$15.43$115,725.0030,500View SEC Filing  
1/3/2017Floyd F PetersenDirectorSell400$18.61$7,444.0058,717View SEC Filing  
12/15/2016Diane G GerstEVPSell2,940$20.51$60,299.4026,195View SEC Filing  
12/5/2016Rong ZhouEVPSell61$20.70$1,262.7036,991View SEC Filing  
12/1/2016Floyd F PetersenDirectorSell400$20.26$8,104.0059,117View SEC Filing  
11/28/2016Jason B ShandellInsiderSell26,335$20.48$539,340.80205,004View SEC Filing  
11/15/2016Howard LeeDirectorSell37,994$20.65$784,576.10134,527View SEC Filing  
10/3/2016Floyd F PetersenDirectorSell400$18.75$7,500.0059,917View SEC Filing  
9/26/2016Jason B ShandellInsiderSell56,996$19.50$1,111,422.00259,957View SEC Filing  
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.971,295,685View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.0060,317View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18125View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00212,961View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.8839,031View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.3226,000View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82202,961View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.0028,653View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.2542,792View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.1363,625View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36208,948View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.7931,681View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.7264,652View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.3537,137View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.0029,086View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72216,610View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.0066,949View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40226,514View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.1928,649View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.0023,000View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.1639,713View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.7139,713View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.0026,200View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.3012,186View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08109,901View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.8825,460View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00920,117View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07920,117View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35920,117View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.0035,722View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amphastar Pharmaceuticals (NASDAQ AMPH) News Headlines

Source:
DateHeadline
How Did Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) 0.09% ROE Fare Against The Industry?How Did Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) 0.09% ROE Fare Against The Industry?
finance.yahoo.com - February 22 at 9:29 AM
Key Factors to Influence Penumbras (PEN) Earnings in Q4Key Factors to Influence Penumbra's (PEN) Earnings in Q4
finance.yahoo.com - February 21 at 9:53 AM
Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Buy" from AnalystsAmphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 13 at 5:36 PM
Amphastar Pharmaceuticals (AMPH) Rating Increased to Hold at BidaskClubAmphastar Pharmaceuticals (AMPH) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - February 10 at 1:06 PM
$60.11 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter$60.11 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter
www.americanbankingnews.com - February 8 at 6:02 AM
What's in Store for Cardinal Health (CAH) in Q2 Earnings?What's in Store for Cardinal Health (CAH) in Q2 Earnings?
finance.yahoo.com - January 30 at 9:21 AM
Insider Selling: Amphastar Pharmaceuticals Inc (AMPH) General Counsel Sells 8,661 Shares of StockInsider Selling: Amphastar Pharmaceuticals Inc (AMPH) General Counsel Sells 8,661 Shares of Stock
www.americanbankingnews.com - January 27 at 12:12 AM
Amphastar Pharmaceuticals Inc (AMPH) Insider Sells $361,736.34 in StockAmphastar Pharmaceuticals Inc (AMPH) Insider Sells $361,736.34 in Stock
www.americanbankingnews.com - January 26 at 9:28 PM
Amphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by Zacks Investment ResearchAmphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 23 at 5:28 PM
Zacks: Analysts Anticipate Amphastar Pharmaceuticals Inc (AMPH) Will Post Quarterly Sales of $62.58 MillionZacks: Analysts Anticipate Amphastar Pharmaceuticals Inc (AMPH) Will Post Quarterly Sales of $62.58 Million
www.americanbankingnews.com - January 22 at 5:42 AM
Amphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by BidaskClubAmphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 21 at 4:58 PM
Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of -$0.04 Per ShareAmphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - January 20 at 3:32 PM
Amphastar Pharmaceuticals Inc (AMPH) Receives Average Rating of "Hold" from AnalystsAmphastar Pharmaceuticals Inc (AMPH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 7:36 PM
How Financially Strong Is Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)?How Financially Strong Is Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)?
finance.yahoo.com - January 9 at 11:14 AM
$62.58 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter$62.58 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter
www.americanbankingnews.com - January 5 at 9:02 AM
Amphastar Pharmaceuticals (AMPH) Lifted to "Hold" at Zacks Investment ResearchAmphastar Pharmaceuticals (AMPH) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 2 at 5:56 PM
An Intrinsic Value Calculation For Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Shows It’s 39.91% UndervaluedAn Intrinsic Value Calculation For Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Shows It’s 39.91% Undervalued
finance.yahoo.com - January 2 at 11:11 AM
Amphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Amphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 11:08 AM
Amphastar Pharmaceuticals (AMPH) Cut to "Sell" at Zacks Investment ResearchAmphastar Pharmaceuticals (AMPH) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - December 27 at 5:00 PM
Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Rating of "Hold" from AnalystsAmphastar Pharmaceuticals Inc (AMPH) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 25 at 6:30 PM
Should You Buy Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) At $19.5?Should You Buy Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) At $19.5?
finance.yahoo.com - December 22 at 9:21 PM
Wired News – Amphastar Pharmaceuticals Declares Approval of ANDA for Sodium Nitroprusside InjectionWired News – Amphastar Pharmaceuticals Declares Approval of ANDA for Sodium Nitroprusside Injection
finance.yahoo.com - December 21 at 11:29 AM
Insider Selling: Amphastar Pharmaceuticals Inc (AMPH) EVP Sells 523 Shares of StockInsider Selling: Amphastar Pharmaceuticals Inc (AMPH) EVP Sells 523 Shares of Stock
www.americanbankingnews.com - December 19 at 9:48 PM
Amphastar Pharma (AMPH) Granted FDA Approval for Sodium ... - StreetInsider.comAmphastar Pharma (AMPH) Granted FDA Approval for Sodium ... - StreetInsider.com
www.streetinsider.com - December 19 at 11:28 AM
Amphastar Announces Approval for Sodium Nitroprusside Injection, USP - GlobeNewswire (press release)Amphastar Announces Approval for Sodium Nitroprusside Injection, USP - GlobeNewswire (press release)
www.globenewswire.com - December 19 at 11:28 AM
Amphastar Announces Approval for Sodium Nitroprusside Injection, USPAmphastar Announces Approval for Sodium Nitroprusside Injection, USP
finance.yahoo.com - December 19 at 11:28 AM
-$0.04 Earnings Per Share Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter-$0.04 Earnings Per Share Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter
www.americanbankingnews.com - December 18 at 3:26 AM
Financial Contrast: Amphastar Pharmaceuticals (AMPH) versus Teligent (TLGT)Financial Contrast: Amphastar Pharmaceuticals (AMPH) versus Teligent (TLGT)
www.americanbankingnews.com - December 16 at 5:16 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells $148,431.42 in StockAmphastar Pharmaceuticals, Inc. (AMPH) Director Sells $148,431.42 in Stock
www.americanbankingnews.com - December 14 at 9:20 PM
Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMPH-US : December 12, 2017Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMPH-US : December 12, 2017
finance.yahoo.com - December 12 at 11:40 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Director Stephen B. Shohet Sells 7,862 SharesAmphastar Pharmaceuticals, Inc. (AMPH) Director Stephen B. Shohet Sells 7,862 Shares
www.americanbankingnews.com - December 8 at 6:20 PM
Amphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USPAmphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USP
finance.yahoo.com - December 8 at 11:40 AM
Amphastar Pharmaceuticals, Inc. (AMPH) CFO Sells $122,465.42 in StockAmphastar Pharmaceuticals, Inc. (AMPH) CFO Sells $122,465.42 in Stock
www.americanbankingnews.com - December 5 at 7:12 PM
 Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Announce Quarterly Sales of $62.58 Million Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Announce Quarterly Sales of $62.58 Million
www.americanbankingnews.com - December 2 at 1:06 PM
Amphastar Pharmaceuticals (AMPH) Price Target Raised to $23.00 at Needham & Company LLCAmphastar Pharmaceuticals (AMPH) Price Target Raised to $23.00 at Needham & Company LLC
www.americanbankingnews.com - December 1 at 8:55 AM
Stephen B. Shohet Sells 7,862 Shares of Amphastar Pharmaceuticals, Inc. (AMPH) StockStephen B. Shohet Sells 7,862 Shares of Amphastar Pharmaceuticals, Inc. (AMPH) Stock
www.americanbankingnews.com - November 30 at 10:34 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Given Average Recommendation of "Hold" by BrokeragesAmphastar Pharmaceuticals, Inc. (AMPH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 7:46 PM
Amphastar Pharma (AMPH) Announces FDA Approval for Medroxyprogesterone Acetate Injectable Suspension, USP - StreetInsider.comAmphastar Pharma (AMPH) Announces FDA Approval for Medroxyprogesterone Acetate Injectable Suspension, USP - StreetInsider.com
www.streetinsider.com - November 30 at 3:34 PM
Zacks: Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Post Earnings of -$0.04 Per ShareZacks: Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Post Earnings of -$0.04 Per Share
www.americanbankingnews.com - November 30 at 1:26 AM
Amphastar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMPH) : November 29, 2017Amphastar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMPH) : November 29, 2017
finance.yahoo.com - November 29 at 3:34 PM
Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : November 28, 2017Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : November 28, 2017
finance.yahoo.com - November 28 at 8:47 AM
What You Must Know About Amphastar Pharmaceuticals Inc’s (AMPH) 0.09% ROEWhat You Must Know About Amphastar Pharmaceuticals Inc’s (AMPH) 0.09% ROE
finance.yahoo.com - November 24 at 11:46 AM
Insider Selling: Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells 7,862 Shares of StockInsider Selling: Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells 7,862 Shares of Stock
www.americanbankingnews.com - November 17 at 10:48 PM
Pacira Announces FDA Advisory Committee Meeting To Review SNDA For EXPAREL® As A Nerve Block For Regional AnalgesiaPacira Announces FDA Advisory Committee Meeting To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia
www.thestreet.com - November 14 at 4:21 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Expected to Announce Quarterly Sales of $69.05 MillionAmphastar Pharmaceuticals, Inc. (AMPH) Expected to Announce Quarterly Sales of $69.05 Million
www.americanbankingnews.com - November 13 at 6:54 PM
FY2020 Earnings Estimate for Amphastar Pharmaceuticals, Inc. Issued By Jefferies Group (AMPH)FY2020 Earnings Estimate for Amphastar Pharmaceuticals, Inc. Issued By Jefferies Group (AMPH)
www.americanbankingnews.com - November 13 at 10:30 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Given New $17.00 Price Target at BMO Capital MarketsAmphastar Pharmaceuticals, Inc. (AMPH) Given New $17.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - November 12 at 10:30 AM
Zacks: Analysts Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) to Post $0.04 Earnings Per ShareZacks: Analysts Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) to Post $0.04 Earnings Per Share
www.americanbankingnews.com - November 11 at 11:12 AM
Amphastar Pharmaceuticals (AMPH) PT Raised to $17 at BMO Capital on 3Q Report; Awaiting Execution With Key ... - StreetInsider.comAmphastar Pharmaceuticals (AMPH) PT Raised to $17 at BMO Capital on 3Q Report; 'Awaiting Execution With Key ... - StreetInsider.com
www.streetinsider.com - November 11 at 9:06 AM
Pacira Pharmaceuticals To Present At Two November Healthcare ConferencesPacira Pharmaceuticals To Present At Two November Healthcare Conferences
www.thestreet.com - November 10 at 7:21 PM

SEC Filings

Amphastar Pharmaceuticals (NASDAQ:AMPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amphastar Pharmaceuticals (NASDAQ:AMPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amphastar Pharmaceuticals (NASDAQ AMPH) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.